2023 annual financial data
Mereo BioPharma Group 2023 Operating cash flow growth
Direct answer
Operating cash flow growth was 56.72%.
Operating income was -28,416,000 USD and net income was -29,466,000 USD.
Operating cash flow was -21,132,000 USD.
Get free Mereo BioPharma Group email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 10,000,000 USD
- Operating income
- -28,416,000 USD
- Net income
- -29,466,000 USD
- Operating cash flow
- -21,132,000 USD